Cargando…

Epidermolytic hyperkeratosis: clinical update

Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Peter Rout, Denice, Nair, Anushka, Gupta, Anand, Kumar, Piyush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512611/
https://www.ncbi.nlm.nih.gov/pubmed/31190940
http://dx.doi.org/10.2147/CCID.S166849
_version_ 1783417689911328768
author Peter Rout, Denice
Nair, Anushka
Gupta, Anand
Kumar, Piyush
author_facet Peter Rout, Denice
Nair, Anushka
Gupta, Anand
Kumar, Piyush
author_sort Peter Rout, Denice
collection PubMed
description Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsible for the keratin proteins, mostly keratin 1 and 10. The features present at birth include erythema and blistering. In adults, the hallmarks include hyperkeratosis, erosions, and blisters. The major symptoms including xerosis, pruritus, and painful fissuring lead not only to cosmetic problems but also stress, inferiority complex and other psychological conditions. While clinical inspection followed by confirmatory tests including histopathology and electron microscopic assessment is used for diagnosis, treatment modalities can be further improved for better diagnosis. This article reviews subtypes of ichthyosis, with a focus on EHK, genetics behind the disease, recently reported mutations, the existing diagnostics and treatments for the same and potential of new modalities in diagnosis/treatment.
format Online
Article
Text
id pubmed-6512611
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65126112019-06-12 Epidermolytic hyperkeratosis: clinical update Peter Rout, Denice Nair, Anushka Gupta, Anand Kumar, Piyush Clin Cosmet Investig Dermatol Review Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsible for the keratin proteins, mostly keratin 1 and 10. The features present at birth include erythema and blistering. In adults, the hallmarks include hyperkeratosis, erosions, and blisters. The major symptoms including xerosis, pruritus, and painful fissuring lead not only to cosmetic problems but also stress, inferiority complex and other psychological conditions. While clinical inspection followed by confirmatory tests including histopathology and electron microscopic assessment is used for diagnosis, treatment modalities can be further improved for better diagnosis. This article reviews subtypes of ichthyosis, with a focus on EHK, genetics behind the disease, recently reported mutations, the existing diagnostics and treatments for the same and potential of new modalities in diagnosis/treatment. Dove 2019-05-08 /pmc/articles/PMC6512611/ /pubmed/31190940 http://dx.doi.org/10.2147/CCID.S166849 Text en © 2019 Peter Rout et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Peter Rout, Denice
Nair, Anushka
Gupta, Anand
Kumar, Piyush
Epidermolytic hyperkeratosis: clinical update
title Epidermolytic hyperkeratosis: clinical update
title_full Epidermolytic hyperkeratosis: clinical update
title_fullStr Epidermolytic hyperkeratosis: clinical update
title_full_unstemmed Epidermolytic hyperkeratosis: clinical update
title_short Epidermolytic hyperkeratosis: clinical update
title_sort epidermolytic hyperkeratosis: clinical update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512611/
https://www.ncbi.nlm.nih.gov/pubmed/31190940
http://dx.doi.org/10.2147/CCID.S166849
work_keys_str_mv AT peterroutdenice epidermolytichyperkeratosisclinicalupdate
AT nairanushka epidermolytichyperkeratosisclinicalupdate
AT guptaanand epidermolytichyperkeratosisclinicalupdate
AT kumarpiyush epidermolytichyperkeratosisclinicalupdate